Intellia Therapeutics

NTLANasdaq United States Health Care Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market cap

$1.668 B

$11.94 +6.23%

Close of 7 Aug 2026

Revenue

$67.7M

#2645 by revenue

Earnings

-$412.7M

Loss-making

Shares outstanding

140,126,693

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: In Vitro & In Vivo Diagnostic Substances — ranked by market cap

All 19 →

#4Celldex TherapeuticsCLDX$3.27B
#5NeogenNEOG$2.50B
#6Intellia TherapeuticsNTLA$1.67B
#7Anbio BiotechnologyNNNN$1.53B
#8QuidelOrthoQDEL$837.7M

Where these numbers come from

Share counts and financials for Intellia Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.